经皮穴位电刺激联合阿片类药物缓解中重度癌痛:随机对照试验方案
主要结局为基线、治疗三周及两周随访时NRS评分变化与吗啡等效剂量,次要结局包括细胞免疫功能、生活质量、阿片类药物副作用及安全性与依从性。
要点
- TEAS联合阿片类药物用于中重度癌痛的疗效与免疫优势尚缺乏研究。
- 主要结局为NRS评分变化和吗啡等效剂量。
- 次要结局包括细胞免疫、生活质量及阿片副作用评估。
核心结论
- 该试验旨在明确TEAS对癌痛是否有效,并验证TEAS联合阿片类药物在改善免疫功能和减少阿片诱导副作用方面的优势。
研究设计与样本
- 多中心、前瞻性、随机对照临床试验方案,计划从中国浙江省两家医院纳入160例中重度癌痛患者。
- 患者随机分为TEAS组和假TEAS组(无穴位电刺激),两组均接受21天化疗间期和常规癌痛治疗。
关键数值与推荐
- 主要结局指标为数值评定量表(NRS)评分变化和吗啡等效剂量。
- 次要结局指标包括细胞免疫功能、生活质量评估、阿片类药物副作用评估以及安全性和依从性评价。
临床怎么用
- 若试验证实有效,TEAS可作为中重度癌痛患者联合阿片类药物的辅助治疗,以改善免疫功能和减少阿片诱导副作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcutaneous electrical acupoint stimulation (TEAS), which is also known as acupuncture-like transcutaneous electrical nerve stimulation (TENS), has been widely used in acute or chronic pain. However, previous research has not demonstrated that TEAS is effective for cancer-related pain. Opioid drugs are strongly recommended for treating cancer-related pain, but opioid-induced immunosuppression is still the most intractable drug-induced medical problem. Evaluating the efficacy and potential advantage of TEAS combined with opioid drugs in moderate and severe cancer-related pain in China is important because such studies are lacking. METHODS/DESIGN: This trial is a multicenter, prospective randomized controlled clinical trial. In total, 160 patients who were enrolled from two hospitals in the Zhejiang Province (China) will be randomly allocated into two groups: a TEAS group and sham TEAS group without acupoint electrical stimulation. Both groups will receive a 21-day interval of chemotherapy and conventional cancer pain therapy. Fifteen treatment sessions will be performed over a three-week period. The primary outcomes will be measured by changes in the Numerical Rating Scale (NRS) scores and equivalent dosage of morphine at baseline, three weeks of treatment and one two-week follow-up. The secondary outcome measures include cellular immunity function, life quality assessment, opioids side effects assessment, and safety and compliance evaluation. DISCUSSION: This trial is expected to clarify whether TEAS is effective for cancer-related pain. These results demonstrate the advantage of TEAS combined with opioid drugs on improving immune function and decreasing opioid induced side effects. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR-13003803 . Registered on 27 August 2013.
引用
- Liang Y, Bao G, Gong L, et al. Evaluating the analgesic effect and advantage of transcutaneous electrical acupoint stimulation combined with opioid drugs for moderate to severe cancer-related pain: a study protocol for a randomized controlled trial. Trials. 2019. PMID: 30635007. doi:10.1186/s13063-018-3145-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。